// App-Quantinova.ai

OC 30.5 : Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

Researchers

Presenter

  • C. Hermans

Principal Investigators

  • C. Negrier

  • M. Lehle

  • P. Chowdary

  • V. Jimnez Yuste

  • C. Schmitt

  • J. Windyga

  • A. Kiialainen

  • R. d'Oiron

  • P. Moorehead

  • A. Shapiro

  • J. Oldenburg

Medical Centers

  • Cliniques Universitaires Saint-Luc and UCLouvain, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

  • Claude Bernard Lyon 1 University, Lyon, France

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • The Royal Marsden Hospital, London, United Kingdom

  • Hospital Universitario La Paz, Autonoma University, Madrid, Spain

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • CRC-MHC, Hôpital de Bicetre AP-HP, Le Kremlin Bicetre, France, Le Kremlin Bicêtre, Ile-de-France, France

  • Memorial University of Newfoundland, Newfoundland and Labrador, Canada.

  • UCSF, San Francisco, California, United States

  • F. Hoffmann-La Roche Ltd., Basel, California, United States

  • Indiana Haemophilia andThrombosis Center, Indianapolis, IN, United States

  • University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany

Locations

  • Belgium

  • France

  • Switzerland

  • United Kingdom

  • Spain

  • Poland

  • Canada

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • NCT04158648

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved